PRINCETON, December 22, 2022: Morgan Lewis represented Merck in its exclusive license and collaboration agreement with Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd., to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. Under the terms of the agreement, Merck will give Kelun-Biotech upfront payment of $175 million and Kelun-Biotech is also eligible to receive future development, regulatory, and sales milestone payments totaling up to $9.3 billion.
Merck, a global biopharmaceutical company known as MSD outside the United States and Canada, is focused on using science to save and improve lives around the world, including translating breakthrough science into innovative oncology medicines to help people with cancer worldwide. Kelun-Biotech is a clinical-stage biotech company focused on biologic and small molecule discovery and development.
Morgan Lewis partner David Glazer and associate Natalie Nicelli, along with partner Todd Liao, senior counsel Scott Kauffman, and associate Omobolaji Bedu, represented Merck.